SOPHiA Genetics (NASDAQ:SOPH) issued its earnings results on Wednesday. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.08, MarketWatch Earnings reports.
Shares of NASDAQ:SOPH opened at $17.42 on Friday. SOPHiA Genetics has a 12 month low of $14.88 and a 12 month high of $19.80.
SOPH has been the topic of a number of research reports. JPMorgan Chase & Co. assumed coverage on SOPHiA Genetics in a research note on Tuesday, August 17th. They issued an “overweight” rating and a $23.00 price objective on the stock. Morgan Stanley began coverage on shares of SOPHiA Genetics in a research note on Tuesday, August 17th. They set an “overweight” rating and a $24.00 price target on the stock. Credit Suisse Group began coverage on shares of SOPHiA Genetics in a research note on Tuesday, August 17th. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Cowen started coverage on SOPHiA Genetics in a research report on Tuesday, August 17th. They set an “outperform” rating on the stock.
SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Receive News & Ratings for SOPHiA Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA Genetics and related companies with MarketBeat.com's FREE daily email newsletter.